Analyst Price Targets — TLX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 9:02 pm | — | RBC Capital | $18.00 | $10.83 | TheFly | Telix Pharmaceuticals downgraded to Sector Perform from Outperform at RBC Capital |
| December 15, 2025 1:11 am | — | RBC Capital | $17.00 | $9.02 | TheFly | Telix Pharmaceuticals initiated with a Sector Perform at RBC Capital |
| September 23, 2025 12:36 pm | Laura Sutcliffe | UBS | $20.00 | $10.92 | TheFly | Telix Pharmaceuticals price target lowered to $20 from $23 at UBS |
| September 10, 2025 12:22 pm | Robert Burns | H.C. Wainwright | $20.00 | $9.69 | TheFly | Telix Pharmaceuticals price target lowered to $20 from $23 at H.C. Wainwright |
Latest News for TLX
MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga68 gozetotide injection) for…
MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appointed Chair of the Board, effective immediately.
Telix Pharmaceuticals has rebounded strongly, reaching profitability and guiding FY2026 revenue to $950–$970 million, driven by precision medicine sales. Key catalysts include imminent FDA decisions for TLX101-Px (brain tumor imaging) and resubmission plans for TLX250-Px (kidney cancer imaging). TLX's radiopharmaceutical pipeline advances with pivotal studies in prostate cancer diagnostics and therapeutics,…
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
Telix Pharmaceuticals NASDAQ: TLX reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The company said EBITDA increased 146% year over year to $52 million, while net profit after tax rose to $38 million.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TLX.
U.S. House Trading
No House trades found for TLX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.